All business news articles – Page 3
-
NewsAstraZeneca and Daiichi’s Enhertu wins first-in-decade US oncology approval
FDA approval of the drug in combination with Perjeta initiates a $150 million milestone payment to Daiichi Sankyo from AstraZeneca under their joint collaboration.
-
NewsCHMP recommends cancer medicines by SFL Pharmaceuticals and Serum Life Science Europe
The EMA’s human medicines committee also recommended approval of drugs by GSK, Moderna, STADA, Lupin Europe and Cytokinetics.
-
NewsNanexa collaboration to enhance Moderna’s mRNA drug delivery
Moderna’s $500 million deal with Nanexa will focus on improving long-acting injectable drug delivery, potentially improving mRNA medicines.
-
NewsLilly to establish third new US manufacturing facility in Alabama
Announcement of Eli Lilly and Company's fourth new US manufacturing plant is expected within the next few weeks.
-
NewsPfizer boosts its obesity plans with $2bn GLP-1 YaoPharma deal
The move builds on its recent billion-dollar acquisition of the obesity-focused biopharma company Metsera.
-
NewsTakeda expands its ADC and immuno-oncology pipeline as Innovent deal closes
The $11bn collaboration with the Chinese biopharma company gives Takeda the rights to several next-generation candidates.
-
NewsLife sciences responds to 2025 UK Autumn Budget
The modern Industrial Strategy is informing the UK government’s decisions in the Budget.
-
NewsNovartis adjusts manufacturing strategy in Switzerland to secure competitiveness
Swiss pharma company to trim production of oral medicines and packaging in Stein, while boosting productivity in Schweizerhalle.
-
News
AstraZeneca furthers US manufacturing commitment with $2bn Maryland investment
The move is part of biopharma's $50 billion pledge to US medicines manufacturing and R&D.
-
NewsModerna strengthens US mRNA manufacturing capabilities with over $140m investment
The expansion places the pharma company’s full manufacturing loop in the US under one roof.
-
News
Johnson & Johnson targets oncology portfolio with $3bn Halda acquisition
Acquisition of the US biotech gives Johnson & Johnson rights to clinical-stage precision treatments for solid tumours.
-
NewsGenetically engineered iPSCs see clinical-scale platelet manufacturing potential
By utilising patient-derived instead of donor-derived platelets, the method could offer a safer approach to platelet transfusions.
-
NewsLilly bolsters leadership team with neuroscience and immunology in mind
Dr Carole Ho joins from Denali Therapeutics and there are promotions for Adrienne Brown and Daniel Skovronsky.
-
News
Lilly boosts oral GLP-1 manufacturing capability with new Netherlands facility
The €2.6 billion manufacturing investment complements the recent US manufacturing expansion for its next potential blockbuster obesity treatment orforglipron.
-
News
Pfizer and Novo Nordisk battle for obesity market dominance
Novo Nordisk’s “bold” $6.5 billion bid subject to a final verdict by Metsera’s board of directors.
-
News
AI reshapes pharma recruitment, but skills gaps, culture and bias temper gains
Cultural change inside pharma needed to help attract tech talent and support a deeper adoption of AI in the industry, say recruiters at CPHI Frankfurt 2025.
-
News
CPHI Pharma Awards 2025 reward Fujifilm, RezonBio and Esteve leaders
Winners at the ceremony in Frankfurt also included CNX Therapeutics, NunaBio, Evonik Industries and Corden Pharma.
-
NewsAI expert warns pharma industry: artificial intelligence is a competitor, not just a tool
Speaking at CPHI Frankfurt, Bruno Fabre underlined the importance of companies viewing the technology as a fundamental business capability, rather than “an afterthought”.
-
News
Lilly AI factory to accelerate pharmaceutical manufacturing and development
Pharma giant plans to harness its “decades of data” and use AI to set a new scientific standard that accelerates pharmaceutical innovation.
-
NewsEnsera talks integrated design-to-manufacture model at CPHI Frankfurt 2025
Model offers mid market innovators and larger pharma companies tailored processes and scale capacity without compromising compliance.